STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and more

Germany's new legislation aims to significantly increase the discount rates that pharmaceutical companies must offer for branded medicines, a move that could reshape the country's healthcare costs and drug pricing dynamics. This bill reflects growing pressure on drug companies to reduce prices in a nation where healthcare affordability is a critical issue. Meanwhile, there's a concerning trend of drugmakers increasingly adopting secrecy around their pricing strategies, which could further complicate negotiations and transparency in the healthcare sector. This shift not only impacts consumer costs but also has broader implications for healthcare policy and industry ethics.